AMNEAL PHARMACEUTICALS

Lobbying for AMNEAL PHARMACEUTICALS · Pharmaceutical company

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Expenses

$340,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

New Jersey

Official filing document

Government bodies contacted 3

HOUSE OF REPRESENTATIVES
SENATE
White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 1

Health Issues

Addressing drug shortages and enhancing domestic production of critical medicines Issues and proposed legislation related to long-term sustainability of access for patients to generic and biosimilar medicines, including but not limited to pharmaceutical supply chain security, drug shortages, biosimilar interchangeability, and PBM reform Issues related to Medicaid Generics Penalty Issues related to possible drug shortage of levothyroxine capsules Issues related to tariffs Appropriations for increasing domestic manufacturing of generic medicines Issues related to NDAA

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.